PSMA Targeted Molecular Imaging and Radioligand Therapy for Prostate Cancer: Optimal Patient and Treatment Issues
, Kei Yaginuma, Satoru Meguro, Akifumi Onagi, Kanako Matsuoka, Junya Hata, Yuichi Sato, Hidenori Akaihata, Masao Kataoka, Soichiro Ogawa, Motohide Uemura and Yoshiyuki Kojima
Round 1
Reviewer 1 Report
In this manuscript, authors provide a comprehensive overview on the PSMA based radiotheranostics for prostate cancer. The enumerated clinical trails of PSMA-RLT will be helpful to guide the prostate cancer theranostics. Minor suggestions are listed below:
1. Could authors also discuss the related application of 90Yttrium-PSMA in the RLT of prostate cancer.
2. Could authors discuss the potential of nanoparticle based PSMA-RLT, such as but not limited to radiolabeled gold nanoparticle.
Author Response
We would like to express our deepest gratitude to the reviewers who have spent their valuable time thoroughly reviewing our manuscript. Your insightful comments and constructive feedback significantly improved the quality of our work. The criticisms and suggestions provided were immensely helpful in refining our study, making it much stronger and more robust. We sincerely appreciate your contribution to enhancing the scientific value of our research.
Responses to the peer review are as follows;
- Could authors also discuss the related application of 90Yttrium-PSMA in the RLT of prostate cancer.
We thank the reviewers for their comments. We've made the necessary changes in our paper as suggested. Your feedback has truly improved our study. “90Y-PSMA-617, which employs the β-ray emitting radionuclide 90Y, holds the potential to reduce xerostomia and blood toxicity in comparison to 177Lu-PSMA-617” p8 302-306
- Could authors discuss the potential of nanoparticle based PSMA-RLT, such as but not limited to radiolabeled gold nanoparticle.
We thank the reviewers for their comments. We've made the necessary changes in our paper as suggested. Your feedback has truly improved our study. “3.2.4 PSMA-targeted nanoparticles
Nanoparticles (NPs) such as polymer, DNA polyplexes, lipid particles, liposomes, metals, and proteins have been developed regard to ligand molecules that target PSMA[72]. NPs targeting PSMA with metals such as iron oxide [73] and gold [74], polymers [75] and liposomes [76] have been developed and are expected to be used clinically in the future. ” p9 363-368
Author Response File: 
Author Response.docx
Reviewer 2 Report
Comments for author File: 
Comments.pdf
Author Response
We would like to express our deepest gratitude to the reviewers who have spent their valuable time thoroughly reviewing our manuscript. Your insightful comments and constructive feedback significantly improved the quality of our work. The criticisms and suggestions provided were immensely helpful in refining our study, making it much stronger and more robust. We sincerely appreciate your contribution to enhancing the scientific value of our research.
Author Response File: Author Response.docx
Reviewer 3 Report
This is a complete and very detailed review of the new tracers used both in diagnosis/staging and in the treatment of prostate cancer patients . The work is well written and adequately underlines the aspects still to be clarified both in the diagnostic field but above all in the therapeutic one.
Minor text adjustments are needed: remove the text in brackets from line 251 and arrange better table 5
Author Response
We would like to express our deepest gratitude to the reviewers who have spent their valuable time thoroughly reviewing our manuscript. Your insightful comments and constructive feedback significantly improved the quality of our work. The criticisms and suggestions provided were immensely helpful in refining our study, making it much stronger and more robust. We sincerely appreciate your contribution to enhancing the scientific value of our research.
Responses to the peer review are as follows;
Minor text adjustments are needed: remove the text in brackets from line 251 and arrange better table 5
Thank you for pointing this out. We have removed the text as you pointed out and revised the position of the text in the table to make it easier to read.
Author Response File: Author Response.docx
Reviewer 4 Report
This article is very informative and includes the outcomes of the most recent studies on the clinical application of PSMA-targeted diagnostics and therapy. In addition, it provides updates on the current approval status of radiopharmaceuticals targeting this receptor for prostate cancer theranostics and presents their clinical limitations.
In Table 4, please replace the 2nd "Trial for mHSPC" with "Trial for mCRPC"
Author Response
We would like to express our deepest gratitude to the reviewers who have spent their valuable time thoroughly reviewing our manuscript. Your insightful comments and constructive feedback significantly improved the quality of our work. The criticisms and suggestions provided were immensely helpful in refining our study, making it much stronger and more robust. We sincerely appreciate your contribution to enhancing the scientific value of our research.
Responses to the peer review are as follows;
In Table 4, please replace the 2nd "Trial for mHSPC" with "Trial for mCRPC"
Thank you for pointing this out. We have corrected the error as you indicated.
Author Response File: Author Response.docx
